Last reviewed · How we verify
NCT02727400: Mitenergy
Mitochondrial Energy Production in ART (Assisted Reproductive Technology )
trial in Female Infertility Due to Advanced Maternal Age in 60 participants. Completed in 16 April 2018.
16 April 2018
Quick facts
| Lead sponsor | IVI Madrid |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 April 2017 |
| Primary completion | 16 April 2018 |
| Estimated completion | 16 April 2018 |
| Sites | 1 location across Spain |
Conditions studied
- Female Infertility Due to Advanced Maternal Age — all drugs for Female Infertility Due to Advanced Maternal Age →
Sponsor
IVI Madrid — full company profile →
Who can join
Adults 18 to 46, female only, with Female Infertility Due to Advanced Maternal Age. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Oocyte maturation requires a lot of energy, which is provided by the mitochondria via the synthesis of ATP. The majority of patients with advanced maternal age (AMA) have poor egg quality. One of the reasons depends on oxidative phosphorylation of Pyruvate to undergo maturation; on the contrary, the cells of the cumulus (CC) show great activity glycolytic so that these cells are able to provide ATP(adenosine triphosphate and energy substrates to the oocyte. The goal of this work is to analyze the mitochondrial function and energy production in oocyte donors compared with a group of women of advanced maternal age subject to a same ovarian stimulation Protocol
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02727400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other IVI Madrid trials
Trials by the same sponsor.
- NCT06244745 — Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors. · Phase 3 · recruiting
- NCT05606679 — Maternal KIR and Fetal HLA Influence Reproductive Success in ART-oocyte Donor. · unknown
- NCT05508217 — Impact of Telomere Biology and Sperm DNA Fragmentation on Embryonic Development · unknown
- NCT02718105 — Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate · completed
- NCT04778358 — Higher Dose of Rekovelle in Oocyte Donors · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02727400 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IVI Madrid
- Last refreshed: 17 April 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02727400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing